Clearbridge Investments LLC Purchases 6,123 Shares of Sanofi (NASDAQ:SNY)

Clearbridge Investments LLC boosted its position in Sanofi (NASDAQ:SNYGet Rating) by 4.6% during the second quarter, HoldingsChannel.com reports. The fund owned 139,680 shares of the company’s stock after buying an additional 6,123 shares during the quarter. Clearbridge Investments LLC’s holdings in Sanofi were worth $6,988,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. Bank of America Corp DE increased its stake in Sanofi by 14.4% in the first quarter. Bank of America Corp DE now owns 12,051,921 shares of the company’s stock valued at $618,746,000 after acquiring an additional 1,512,434 shares during the last quarter. Boston Partners grew its stake in shares of Sanofi by 62.3% during the first quarter. Boston Partners now owns 11,272,368 shares of the company’s stock worth $580,302,000 after buying an additional 4,328,799 shares during the last quarter. Invesco Ltd. grew its stake in shares of Sanofi by 2.3% during the first quarter. Invesco Ltd. now owns 5,077,848 shares of the company’s stock worth $260,697,000 after buying an additional 112,404 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of Sanofi by 276.1% during the first quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company’s stock worth $172,611,000 after buying an additional 2,468,271 shares during the last quarter. Finally, Lazard Asset Management LLC grew its stake in shares of Sanofi by 0.8% during the first quarter. Lazard Asset Management LLC now owns 3,321,721 shares of the company’s stock worth $170,536,000 after buying an additional 25,457 shares during the last quarter. 10.33% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on SNY. StockNews.com began coverage on shares of Sanofi in a research note on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Cheuvreux cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Wednesday, August 24th. Barclays decreased their target price on shares of Sanofi from €105.00 ($107.14) to €85.00 ($86.73) and set an “equal weight” rating on the stock in a research note on Friday, October 14th. UBS Group cut shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 9th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on shares of Sanofi from €90.00 ($91.84) to €85.00 ($86.73) and set a “hold” rating on the stock in a report on Wednesday, September 7th. Five analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $102.88.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $45.04 on Friday. The firm has a market cap of $114.17 billion, a PE ratio of 16.32, a price-to-earnings-growth ratio of 1.05 and a beta of 0.59. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.34 and a current ratio of 1.29. Sanofi has a 52 week low of $36.91 and a 52 week high of $58.10. The firm’s fifty day moving average is $41.63 and its 200-day moving average is $42.36.

Sanofi Profile

(Get Rating)

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.

See Also

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNYGet Rating).

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.